Introduction and Aims: Vertebral Fractures (VFs) are common in the general population and in Chronic Kidney Disease patients. VFs are associated with vascular calcifications (VCs) and to an increased risk of mortality. The Spine Deformity Index (SDI) is a summary measure of the VFs status, incorporating both the number and severity of VFs in a score. The aim of this study was to evaluate the relationships between the classic SDI, laboratory parameters of bone metabolism, and vascular calcifications within the context of the EVERFRACT study. Methods: In 387 hemodialysis patients, aged 64.2 ± 14.1 years, we determined routine biochemical parameters and: 25(OH)vitamin D, total Bone Gla Protein (BGP), undercarboxylated BGP (ucBGP) and total Matrix Gla Protein (MGP). We performed laterolateral x-Rays of the spine (T5 to L4) to evaluate both VFs (defined as reduction > 20% in vertebral body height) by Quantitative Vertebral Morphometry and VCs, aortic (AoVC) and iliac (IaVC), by Witteman's method. We divided the SDI score by the number of fractures, in order to obtain a more precise index of fracture severity (corrected-SDI: c-SDI). Results: We found a high prevalence (55.3%, n=214) of VFs. The mean SDI was 1.4 ± 1.74. The mean c-SDI was 0.74 ± 0.75. VFs had a grade of severity that was low through T5-T10 and higher through T11-L3. The severity of fractures was highlighted only by c-SDI (see Table) . We found 80.6% of AAoC and 55.6% of IAC. SDI was significantly associated with AAoC (OR=1.15, 95% CI 1.02-1.30, p=0.023). A SDI >1 was significantly associated with: sex (male OR 1.86, 95% CI 1.20-2.91, p=0.007), age (OR 1.03, 95% 1.01-1.05, p=0.0003) and albumin ≥ 3.5 g/dL (OR 0.54, 95% CI 0.31-0.93, p=0.026). c-SDI score was significantly associated with AAoC (OR=1.48, 95% CI 1.11-1.98, p=0.0009) and with IAC (OR=1.54, 95% CI 1.06-2.24, p=0.025). A c-SDI >1 was significantly associated with: age (OR 1.05, 95% CI 1.03-1.07, p<0.0001), LDL Cholesterol ≥ 90 mg/dL (OR 1.74, 95% 1.04-2.92, p=0.0354) and ucBGP ≥ 17.2 mcg/L (OR 0.35, p=0.0025). Conclusions: SDI and c-SDI score associated with bone and vascular markers. c-SDI score performed better in the evaluation of the grade of fracture severity and it showed a stronger association with VC and vascular markers. This is the first time that the association of SDI with bone biochemical parameters and VC has been reported. Introduction and Aims: We previously reported that PTH(1-84)/intact PTH ratio provides the most clinically relevant marker for parathyroid function and the resultant bone turnover state. The purpose of our study was to investigate the association of PTH (1-84)/intact PTH ratio with all-cause mortality (ACM) in male hemodialysis patients. Methods: The study was performed for 70 months. Serum PTH in 177 male hemodialysis patients was measured with PTH(1-84)-specific whole PTH assay, and intact PTH assay which cross-reacts with N-truncated PTH including PTH(7-84).
Introduction and Aims: Chronic kidney disease has been described as a state of accelerated ageing. Our task as nephrologists is to slow this process down, but levels of recently discovered biomarkers such as klotho or FGF-23 haveńt found their way into clinical routine as yet. In this article we propose the correlation of serum alkaline phosphatase (SAP) levels with age as a new, easily obtainable quality criterion for the overall management of calcium-phosphate-metabolism in any given cohort of dialysis patients.
SP570 SDI and c-SDI by vertebra in all patients (*The severity of fractures was highlighted by c-SDI)
Vertebra
Mild VF Score1 (n,%)
Moderate VF Score2 (n,%)
Severe VF Score3 (n,%) SDI c-SDI Methods: We compared two dialysis units in New York and Innsbruck, Austria, for chronic kidney disease related mineral and bone disorder (CKD-MBD) parameters and calcium-sensing receptor gene polymorphism. Correlation of SAP with age was then tested in one centre over time (Coburg Dialysis Centre 2009 -2013 and in the centres participating in the Austrian Dialysis and Transplant Registry in 2013.
Results: We found that the correlation of SAP with age, as it is known in healthy adult populations, may be lost in dialysis patients, as it was the case in the New York unit. It may even be replaced by a correlation with dialysis vintage rather than age, in genetically defined subgroups such as female calcium-sensing-receptor gene SNP rs1042636 homozygotes. In the Coburg centre SAP correlation with age was preserved in all years ( p 0.04 to <0.0001) except 2013. In this year two outliers were identified, who both had metastasizing prostate cancer with bone metastases. In a majority of centres in the Austrian registry SAP correlation with age was preserved in 2013.
Conclusions: Considering the necessity to regionalize treatment targets within the fairly wide ranges of KDIGO recommendations, patient sub-populations found to be outliers in a centrés SAP-age-correlation curve may require special attention in terms of CKD-MBD treatment.
SP573 MINERAL AND BONE DISORDER (MBD) MANAGEMENT IN HEMODIALYSIS (HD) PATIENTS FROM THE DOPPS IN THE GULF COOPERATION COUNCIL (GCC) COUNTRIES
Introduction and Aims: The prospective cohort Dialysis Outcomes and Practice Patterns Study (DOPPS) initiated data collection in national samples of HD units (total of 40 study sites) in all 6 GCC countries (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates) in late 2012. Here we report initial results regarding MBD management in the GCC versus that in 3 other DOPPS study regions, as MBD markers have been shown to be strongly related to all-cause and cardiovascular mortality in prior studies. Methods: 40 randomly selected HD facilities, treating >23 HD pts each, were sampled, and represent care for >95% of GCC HD pts. Descriptive results for the GCC, based upon a random sample of 20-30 HD pts in each study facility, are compared to 3 other DOPPS regions. Initial results for the GCC are from 828 HD pts treated at 35 dialysis units (ranging from 1 unit in Bahrain to 20 in Saudi Arabia). Results are presented as weighted estimates, accounting for the sampling fraction in each unit.
Results: Mean age of HD patients in the GCC was 53 yrs versus 61-64 yrs in the 3 other DOPPS regions (Table) . MBD markers showed slightly lower mean S Ca in the GCC, similar mean S Phos, and intermediate median PTH levels compared with the 3 other DOPPS regions. Among GCC countries, the country mean value of MBD markers ranged from 8.6 to 9.0 mg/dL for S Ca, 4.4 to 5.4 mg/dL for S Phos, while median PTH ranged from 163 to 389 pg/mL. Similar to other DOPPS regions, PTH was higher among patients who were younger or without diabetes, and S Phos was lower with older age ( p<0.001 for each). History of parathyroidectomy was lower in the GCC vs other regions but did not differ when adjusted for age and dialysis vintage. Among treatments used for managing MBD, the GCC showed one of the highest uses of cinacalcet (24%) and P-binder use (81%), while IV vitamin D use (24%) was slightly higher than that in EUR-ANZ. A much larger fraction of HD pts in the GCC had a dialysate Ca level >3.5 mEq/L (43%) versus 0 to 4% in the 3 other DOPPS regions. Conclusions: Although many aspects of MBD management and MBD marker achievement are similar in the GCC to that seen in 3 other large DOPPS study regions, large variability is seen across countries and facilities in the GCC. Mean serum calcium was lower in the GCC despite much greater use of dialysate Ca of~3.5 mEq/L which may be due to the relatively low use of vitamin D and higher cinacalcet use, meriting further study. Future work will focus on GCC facility HD practices and patient characteristics most strongly related to achievement of MBD target levels and associated outcomes. Introduction and Aims: The distribution and shifts of calcium during and between dialysis sessions depend on many factors, as calcium concentration in dialysis fluid, levels of hormones that control mineral metabolism, and calcium intake. We present a quantitative assessment of calcium kinetics and mass balance in extracellular compartment during the weekly cycle of three hemodialysis sessions with standard calcium concentration. Methods: Eighteen patients on HD were examined during three consecutive HD sessions of one week dialysis treatment cycle (with the interdialytic breaks of 2-2-3 days) and before the fourth session. Total and ionic calcium concentrations were measured in serum before, at 1, 2 and 3 h, at the end and 45 min after each session and every 30 min in dialysate. The volume of extracellular water was assessed by bioimpedance (BCM) before, at the end, and 45 min after each session. The concentration of calcium in dialysis fluid was 1.25 mmol/L. Results: The concentration of calcium in plasma before dialysis was 8.7 ± 0.7 mg/dL with 43.6% in ionic form, increased during dialysis sessions to 9.4 ± 0.6 mg/dL ( p < 0.001) with 42.6% ( p < 0.005) in ionic form, and slightly decreased at 45 min after the end of dialysis to 9.1 ± 0.5 mg/dL ( p < 0.001 vs. start and vs. end of dialysis session) without any further change in percentage of ionic form. In contrast, the extracellular calcium mass decreased from 1322 ± 241 mg at the beginning of dialysis session, to 1226 ± 242 mg at the end of dialysis session (mostly because of the decrease in extracellular volume by 2.1 ± 0.8 L due to ultrafiltration) and further to 1188 ± 241 mg after 45 min from the end of dialysis session (mostly because of the drop in calcium concentration, all changes with p < 0.001). The changes in calcium mass during the first dialysis session (after 3 days of interdialytic break) were from 1474 ± 189 to 1384 ± 240 to 1366 ± 206 mg, respectively, whereas during the second and third dialysis sessions (both after 2 days of interdialytic break) were from 1254 ± 232 to 1148 ± 204 to 1114 ± 216 mg, respectively. The changes in ionic calcium followed the patterns for total calcium. The net decrease in total calcium mass in extracellular compartment during dialysis of 93 ± 104 mg was similar to and correlated with calcium mass removed in dialyzer (52 ± 244 mg, NS; rho = 0.33, p = 0.018); it was correlated also with absorption of ionic calcium in dialyzer (rho = 0.64, p < 0.001) and tended to correlate with the removal of diffusible calcium complexed to small anions fluid in dialyzer (rho = -0.26, p = 0.059).
SP574 CHANGES IN CALCIUM CONCENTRATION AND MASS IN EXTRACELLULAR COMPARTMENT DURING ONE WEEK CYCLE OF HEMODIALYSIS
Conclusions: We conclude that in hemodialysis patients on standard (1.25 mmol/L) concentration of calcium in dialysis fluid, the concentrations of total and ionic calcium in the extracellular compartment increase during dialysis sessions and decrease between the sessions, whereas the masses of total and ionic calcium decrease during the sessions and increase between them. The weak correlations between the changes in extracellular calcium mass and the removed calcium mass may be linked to the importance of the opposite transport of ionic and complexed forms of calcium in the SP572 SP573 dialyzer and the role of the other calcium pools in the maintenance of calcium mass balance in the extracellular compartment. Introduction and Aims: Despite strong evidence from published clinical studies and 9 years of post-launch monitoring of safety data, concerns over the long-term safety of lanthanum carbonate (LC) persist. The aims of this evaluation were to review the evidence from key publications pertaining to the long-term safety profile of LC, and to present data from a long-term study of LC safety (SPD405-402; ClinicalTrials.gov: NCT00557323). Methods: Key publications reporting LC pharmacokinetic and long-term safety data were identified in PubMed. SPD405-402 study: patients who had enrolled in a previous safety study of up to 6 years of LC monotherapy (Hutchison et al. 2006 ) were eligible to be included in a 5-year, multicenter, observational follow-up study in which patients were assessed for bone-related adverse events (AEs), serious AEs and death.
Results: Review of key published LC safety dataPharmacokinetics. The absolute bioavailability of an oral lanthanum dose is extremely low (~0.001%); by comparison, 0.01-0.1% of dose of aluminum is absorbed. Whereas aluminum is principally excreted by the kidneys, 80% of an oral lanthanum dose is excreted in the feces via the hepatobiliary system; renal clearance accounts for only 1.7% of the total plasma clearance of lanthanum. Lanthanum pharmacokinetics in patients with normal renal function are similar to those with ESRD. BoneAnalysis of bone biopsy studies after up to 5 years of LC treatment revealed no evidence of aluminum-like accumulation or toxicity, or mineralization defects. On the contrary, the data obtained in those studies indicated a greater improvement in adynamic bone disease following treatment with LC compared with standard treatment. The lanthanum:calcium molar ratio in bone after 4.5 years of LC treatment was estimated to be 2×10-5, compared with an aluminum:calcium molar ratio of 6×10-2 following treatment with aluminum-based binders, arguing against the concern that lanthanum accumulates to high levels in bone. GI tractThe majority of LC adverse drug reactions are related to the GI tract (mainly nausea, diarrhea and flatulence), and are primarily mild/moderate in severity, consistent with those observed with other phosphate binders. LiverPatients treated with LC for up to 6 years showed no clinically relevant changes in liver enzyme or bilirubin levels, and no increase in the incidence of liver-associated AEs. This is not surprising given that lanthanum has been shown to undergo transcellular (endosomal-lysosomalbiliary canalicular) transport from the liver. CNSAnimal toxicology studies using LC doses many times higher than those used in humans demonstrated that lanthanum does not cross the intact blood-brain barrier. The rate of cognitive decline in patients treated with LC was similar to that in patients treated with other phosphate binders. SPD405-402Of the 93 eligible patients who had participated in the Hutchison study, 34 were willing to be enrolled in the 5-year follow-up study. Patients were exposed to LC for a mean (SD) duration of 56.0 (23.0) months (4.7 years); range: 1.25-11 years. Eight patients (23.5%) reported study-emergent bone fractures; none were related to LC treatment. One patient reported a bone-related AE that had a suspected relationship to LC treatment. Conclusions: Published studies evaluating the safety of LC monotherapy have consistently reported that LC is well tolerated, with no evidence of adverse safety outcomes. In patients with a mean duration of LC exposure of 4.7 years, we found no evidence of an increased risk of bone fracture. After~500 000 person-years of post-launch monitoring, there is no evidence that LC is associated with adverse safety outcomes in bone, GI tract, liver or CNS. Royal Gwent Hospital, Newport, United Kingdom Introduction and Aims: CKD-MBD is linked to vascular calcification and increased morbidity and mortality. The optimal therapeutic strategy for managing CKD-MBD in dialysis patients remains unknown. Recent guidelines have focussed on the use on calcium containing phosphate binders and have suggested a limited role for calcimimetics. This audit aims to assess whether the management of CKD-MBD in Wales has changed over the last 3 years. Methods: Data from all the dialysis centres in Wales for a 3-month period was collected. The results from 2013 were compared to a previous all Wales MBD audit from 2010. The dataset included blood results (calcium, phosphate and PTH -mean results over 3 month study period) as well as prescription data for each patient (number and type of medication). Target levels for calcium, phosphate and PTH were defined as those set by the renal association. Results: The number of patients on dialysis in 2010 and 2013 were similar (1193 vs. 1194 respectively). There was an increase in the number of patients on home haemodialysis (60 to 83), whilst the number of patients on PD decreased (226 to 177). The percentage of patients achieving target levels for serum phosphate was broadly similar between 2010 and 2013 (63% vs 64%). The number of patients achieving PTH targets (31% vs 27%) and calcium targets (77% vs 69%) were lower in 2013. The number of patients above the calcium target level of was also lower in 2013 (13% vs 7.9 %). There was no significant change observed in the prescription of calcium containing binders with a third of patients treated with these agents in 2010 and 2013. The number of patients on Sevelamer decreased (44% to 32%), however the number of patients on Lanthanum carbonate increased from 15% to 20%. Cinacalcet use increased from 72 to 125 patients from 2010 to 2013. The total cost of MBD medications (Phosphate binders, Vitamin D and Cinacalcet) dropped from £ 1.2 M in 2010 to £ 1.05M in 2013. Conclusions: This all-Wales study assessed whether or not there has been a change in the management of CKD-MBD between 2010 and 2013. This time period has seen the publication of NICE guidelines (on hyperphosphataemia and updated guidelines on hyperparathyroidism) as well as the publication of the EVOLVE trial. These publications do not, as yet appear to have influenced the management of CKD-MBD in Wales. In spite of the negative findings of EVOLVE, and the NICE guidelines suggesting restricted prescription, there has been an increase in the prescription of cinacalcet. The prescription of calcium containing binders remains unchanged despite NICE advocating their first line use. This likely reflects the well established prescribing patterns of the nephrology community which favours cinacalcet and non calcium binders to the treatments advocated by NICE. Or that patients are established on treatment and reluctant to change. Such patterns are likely to prove resistant to change, especially given the fact that CKD-MBD expenditure does not at present fall under the remit of the Welsh Renal Clinical Network, and as such there is no financial incentive for nephrologists to alter their practice. Introduction and Aims: Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease. The majority of patients with SHPT can be managed by medical treatment and there are many modalities available for medical treatment, but these treatments do not always provide control of the SHPT and some patients require parathyroidectomy (PTX). The short-and long-term impact of PTX on the parameters of mineral bone disease in dialysis patients remains unclear. This study evaluated PTX in SHPT patients for the achievement of bone and mineral parameters recommended by KDIGO clinical practice guideline in dialysis patients. Methods: A retrospective chart review of 80 dialysis patients who underwent PTX from April 2005 to November 2013 at one institution. Serum intact parathyroid hormone (iPTH), calcium (Ca), phosphate (P) and alkaline phosphatase (AP) levels were measured prior to and one (short-term follow-up group, n=80) and 12 months (long-term follow-up group, n= 47) after PTX.
SP578 IMPACT OF PARATHYROIDECTOMY ON THE ACHIEVEMENT OF BONE AND MINERAL PARAMETERS RECOMMENDED BY KDIGO CLINICAL PRACTICE GUIDELINE IN DIALYSIS PATIENTS
Results: The mean age of the patients was 49 years and 62.5% were women. The total PTX with autotransplant was performed in 86% of patients and other patients underwent subtotal PTX. Patients had severely uncontrolled serum iPTH, Ca, P and AP levels before PTX. The table 1 shows a comparison of the parameters in relation to periods of evaluation. The table 2 shows the percentages of cases achieving KDIGO targets. In the long-term follow-up group, 72.4% of patients had serum iPTH levels below 150 pg/mL, 17% were in agreement with the KDIGO and 10.6% had iPTH greater than 500 pg/mL. Conclusions: PTX is effective in treating severe SHPT. However, in long-term follow-up, it cannot achieve all parameters recommended by KDIGO and exposes patients to adynamic bone disease. Tsuruta Clinic, Tokyo, Japan
SP579 OSTEOCALCIN AND AMINO-TERMINAL TELOPEPTIDES OF TYPE 1 COLLAGEN ARE USEFUL FOR EVALUATING SECONDARY HYPERPARATHYROIDISM IN HD PATIENTS
Introduction and Aims: Serum levels of osteocalcin (OC), a bone formation marker, have a good correlation with results of bone biopsies in hemodialysis (HD) patients. Serum levels of cross-linked N-telopeptide of type I collagen (NTx), a bone resorption marker, increase in HD patients. The aim of the present study is to examine correlation between the new bone metabolic markers and conventional markers such as alkaline phosphatase (ALP). Another aim is to examine usefulness of the new markers for evaluating secondary hyperparathyroidism (SHPT) status in HD patients. Methods: We enrolled 143 stable HD patients in the study. We selected ALP, bone-specific alkaline phosphatase (BAP), and intact parathyroid hormone (iPTH) as conventional bone metabolic markers. We examined correlation between the conventional and new bone markers. Next, we evaluated whether the new bone markers show significant difference between two groups, in which the HD patients were divided according to serum iPTH levels.
Results: Serum iPTH levels have a positive correlation with both circulating OC (R 2 = 0.37) and NTx (R 2 = 0.34) levels. The levels of serum ALP have a positive correlation only with serum BAP levels (R 2 = 0.31). The high iPTH group (301 pg/mL < iPTH) showed significantly higher levels in serum OC ( p < 0.0001) and NTx ( p< 0.0001) compared to the low iPTH group. The high group also showed significantly higher in serum levels of ALP ( p = 0.038) and BAP ( p= 0.0006) than the low group. This suggests that the new bone markers may be as useful indicator of SHPT as conventional markers. Conclusions: Serum OC and NTx levels are as useful as serum iPTH and BAP levels for evaluating SHPT status in HD patients. Serum OC and NTx levels show good, positive correlation even though they are different type of bone metabolic markers. Some therapeutic interventions in CKD-MBD could alter serum levels of the markers without evidence. Such effects need to be studied in future clinical trials. Introduction and Aims: Calcimimetics have been shown to have suppressive effects on PTH secretion and parathyroid cell proliferation. However, little is known about the mechanistic change in parathyroid cells when calcimimetics are withdrawn. We studied the response of parathyroid glands to the withdrawal of cinacalcet in 5/6 th nephrectomized uremic rats. Methods: Uremic rats (Nx) were fed a 1.2% high phosphate diet for 2 weeks to develop secondary hyperparathyroidism and then divided by 3 treatment groups: 1) with vehicle (UC), 2) with cinacalcet (15 mg/kg/day, gavage) (Cina), and 3) with cinacalcet and a VDRA 22-oxacalcitriol (OCT: 0.15μg/kg, 3 times a week, intraperitoneally) (Cina +Maxa). After 2 weeks treatment, vehicle and cinacalcet were withdrawn while OCT treatment was continued. Immediately (day 0) and 7 days (day 7) after the withdrawal, blood and parathyroid tissues were obtained. Normal rats with vehicle at day 0 and 7 were utilized as normal controls (NC). Results: Cina and Cina+OCT showed equally and significantly lower PTH than Veh at day 0 whereas PTH in the Cina and Cina+OCT was increased up to indistinguishable levels in the Veh at day 7. Serum P was comparable among Veh, Cina, and Cina+OCT in both day 0 and day 7. Cinacalcet treatment significantly decreased ionized Ca compared with Veh at day 0, and this decrease was restored by day 7. CaSRmRNA was significantly decreased in Veh compared with NC at day 0 and day 7, respectively. This decrease was marginally preserved in both Cina and Cina+OCT at day 0, but the preservation was abrogated at day 7. VDRmRNA showed a similar trend to CaSRmRNA, but the level in Cina+OCT was higher than Cina both at day 0 and day 7. At day 0, PCNAmRNA was significantly increased in Veh compared with NC and this increase was significantly suppressed in Cina and Cina+OCT. At day 7, however, Cina, but not Cina+OCT showed significant increase in PCNAmRNA compared with Veh. Conclusions: These results suggest that, although PTH rebound is not present, simultaneous use of VDRA is preferred regarding parathyroid cell proliferation when cinacalcet is withdrawn. Introduction and Aims: Sclerostin, produced by the SOST gene, is an osteocyte-specific glycoprotein and is presented as a potent inhibitor of bone formation. Dialysis patients are prone to bone abnormalities. In this context, the measurement of sclerostin could be of interest and first studies have demonstrated a potential role of sclerostin in the diagnosis of bone turnover, the prediction of vascular calcification and the mortality. In the present work, we studied the potential role of sclerostin in the prediction of mortality. Methods: Prevalent hemodialysis patients from three independent centers in Liège and surrounding areas, Belgium, were included in this study (Centre Hospitalier Universitaire du Sart Tilman, Centre Hospitalier Régional de La Citadelle, Centre Hospitalier Bois de l'Abbaye de Seraing). The patients were followed after sclerostin measurement and data about global mortality are available at 2 years. Sclerostin was measured with the TECO ELISA (TECO medical, Sissach, CH). Intra-and interassay CV for sclerostin was <10%. We performed a Kaplan-Meier univariate survival analysis. The effect of covariates, including the sclerostin tertile subgroups, on survival was investigated with Cox Proportional Hazards Regression. Results: In our HD patients (n=164), the concentration of sclerostin was 1375 [963; 1830] pg/mL. These concentrations are higher than the median concentration observed in an healthy population 565 [443; 660] pg/mL ( p<0.0001) (Figure 1) . In Table 1 Results: We observed a high correlation between all the assays ranging from 0.9948 (IDS iSYS vs. IDS EIA) to 0.9215 (DiaSorin Liaison vs. Quidel Microvue). However, using the regression equations, the equivalent concentration of a Beckman-Coulter Access value of 10 µg/L can range to 7.7 -14.4 µg/L and of 20 µg/L can range to 16.9 -27.9 µg/L with other assays. According to Beckman-Coulter Access, 13%, 50% and 37% of the patients presented BAP values ≤10, between 10 and 20 and ≥20 µg/L, respectively. Discrepancies are observed when other assays are used (concordance from 10 to 100%). Conclusions: Analytical problems leading to inter-method variation should be overcome to improve the usefulness of this marker in clinical practice. According to correlation results, recalibration of BAP assays is necessary but should not be a major issue. Introduction and Aims: Hypomagnesemia seems to play a role in the pathogenesis of arterial hypertension, endothelial dysfunction and vascular calcifications in dialysis patients. The aim of this long term study was to evaluate the relationship between calcium acetate/magnesium carbonate (CaMg) therapy and cardiovascular risk markers like pulse pressure (PP), left ventricular mass index (LVMI) and valvular calcifications in chronic haemodialysis (HD) patients. Methods: Baseline demographic, clinical, biochemical and ecocardiographic parameters were evaluated prospectively for a 48-month period. Patients started CaMg therapy during the study and were under this phosphate binder for at least 36 months. Results: We studied 206 HD patients with mean age (± SD) of 63.6±14.3 years, 45% female, 26% diabetics, with mean HD time of 42.3±38.6 months. All patients were under post dilution hemodiafiltration with a dialysate Mg concentration of 0.5 mmol/ L. Forty-eight patients were under CaMg therapy, 43 patients under sevelamer (Sev) and 115 were not taking phosphate binders (nPB). Patients taking CaMg presented higher Mg serum levels comparedwith the other 2 groups (CaMg: 0.93±0.13 vsSev: 0.91 ±0.12 vs nPB: 0.82±0.15 mmol/L, p<0.001). Patients under CaMg presented a reduction of PP ( p<0.001) and LMVI( p=0.006) at the end of the study. Also a stabilization of aortic valvular calcifications was observed in the patients taking either CaMg, in contrast with the progression of valvular calcifications that was seen in those under Sev or nPB ( p=0.02). Conclusions: In this 48-month study in a large prevalent HD population the use of CaMg was associated with reduction of PP and LVMI and a stabilization of aortic valvular calcifications. These results should be confirmed in randomized controlled trials.
SP581 SCLEROSTIN CONCENTRATION IS NOT PREDICTIVE OF MORTALITY IN HEMODIALYSIS PATIENTS

SP583 CALCIUM ACETATE/MAGNESIUM CARBONATE THERAPY IS ASSOCIATED WITH A REDUCTION OF LEFT VENTRICULAR MASS INDEX AND LOWER PROGRESSION OF VALVULAR CALCIFICATIONS IN HAEMODIALYSIS PATIENTS
SP584 THE ANALYSIS OF CLEAR SPACE OF PHOSPHATE
Hiroshi Kikuchi 1 , Hisaki Shimada 2 , Ryo Karasawa 1 and Masashi Suzuki 2 1 Toyosaka Hospital, Niigata, Japan, 2 Shinrakuen Hospital, Niigata, Japan Introduction and Aims: Clear space (CS) has been known to be useful for evaluating efficiency of hemodialysis (HD). CS can be used to evaluate removal efficiency of various solutes as well as urea nitrogen (UN). Many studies concerning CS of phosphate (iP) (CSp) has not been reported because the estimated amount of intradialytic iP removal (eRp) has been difficult to provide. We have developed a formula for calculating eRp and reported at EDTA 2011 and 2012. We can easily calculate CSp as CSp=eRp/Pa 0 , where Pa 0 =predialytic serum iP concentration. During HD, UN flows passively into extracellular fluid from intracellular. However, iP flows actively only when it is required. We considered this difference result in a gap between CSp and CS of UN (CSun). The aim of this study is to clarify the difference of CSp and CSun. Methods: Blood sampling were performed in 196 HD sessions of 67 patients. eRp mg/ HD) was calculated using following formula previously reported; eRp=33.06Qb Methods: We enrolled patients who were treated with hemodialysis for at least 6 months with 25 hydroxyvitamin D < 30 ng/mL in this randomized double blind placebo control study (NCT01596842). Omega-3 FA supplementation group was treated with omega-3 FA with a dose of 2.4 gram/day for 12 weeks and placebo group were treated with olive oil for 12 weeks. Cholecalciferol was also supplemented with a dose of 50,000IU/week if baseline 25-hydroxyvitamin D levels are < 15 ng/mL and supplemented with a dose of 10,000IU/week if baseline 25-hydroxyvitamin D levels are 16-30 ng/mL for 12 weeks. We measured changes of 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D concentrations as a primary outcome at baseline, 6weeks and 12 weeks. We also measured erythrocyte membrane FA contents with gas chromatography. Results: Eight patients supplemented with omega-3 FA and 7 patients supplemented with placebo finished this trial. The 25-hydroxyvitamin D levels were significantly increased at 6 weeks and 12 weeks compared to baseline levels in both groups (p < 0.001). The 1, 25-dihydroxyvitamin D levels were increased in omega-3 FA supplemented group (17.7 ± 8.2 vs. 25.1 ± 12.3 pg/mL) compared to baseline levels but were not changed in placebo group (24.1 ± 11.1 vs. 23.2 ± 7.2 pg/mL) compared to baseline levels at 12 weeks. The calcium, phosphorus and intact parathyroid hormone levels were not changed compared to baseline levels at 12 weeks in both groups. Erythrocyte membrane oleic acid and monounsaturated FA contents were significantly decreased and omega-3 index was significantly increased in omega-3 FA supplemented group. Conclusions: Cholecalciferol supplementation definitely increased 25-hydroxyvitamin D levels without increasing calcium and phosphorus levels in hemodialysis patients with insufficient or deficient 25-hydroxyvitamin D levels. Omega-3 FA supplementation may related with the activation of vitamin D but increased 25-hydroxyvitamin D with cholecalciferol supplementation was not related with the activation of vitamin D in hemodialysis patients. Introduction and Aims: Relationship between phosphorus and mortality is proved in healthy and CKD patients. A large cut-off of phosphorus (in the order of 1,0 mg/dl) is established to link mortality in large sample size studies in hemodialysis patients. Also in time-updating phosphorus analysis, there may be additional confounding factors related to linear variables (such as nutritonal exposure variables) and the proportion of cardiovascular disease if considered either in late period or in early period of whole dialysis vintage in this setting of patients. Aim of our study is to assess the type and association's strength of phosphorus with mortality either in early or late periods of follow-up in prevalent hemodialysis patients, considering more close range of phosphoremia(in the order of 0,5 mg/dl). Methods: Out of sixtyeight hemodialysis patients, forty one prevalent hemodialysis patients (> 6 months hemodialysis period) are followed up for five years (January 2008-december 2012). The sample is considered in two different periods : early and late twelve months (Early (n41)and Late (n37) groups)[in the late group minimum follow-up of twelve moths is required). Same univariate(T0 variables) and multivariate (case mix, dialysis elapsed time, Phosphorus and singular exposure variables [Calcium, PTH,FA,CaxP, albumin, creatinin,ferritina, Karnofsky score, Hb and cardiovascular diseases]) analysis are performed to estimate proportional hazard ratios of outcomes (all cause and cardiovascular mortality) for seven cut-offs of phosphorus levels (mg/dl) (=/>3,7;=/>3,9;=/>4,4;=/>5,25;=/>5,75; =/>5,95; =/>6). Interaction for albumin is performed in both groups. All exposure variables are time-varyng variables (any date is median of four months determinations). P 0,05 is considered significancy. Results: Fortyone prevalent hemodialysis patients are followed-up for 34 months(SD 18,5). All patients are censored for events (17% CV mortality ; 34% all cause mortality). By univariate analysis, Dialysis vintage, age and Karnofsky score (T0 Variables) are correlated to both outcomes (cardiovascular and all cause mortality) either in early or late group. Generally,in both groups Age, Karnofsky score and Allbumin have the better proprtionality of HRs(Shoenfeld scale residuals vs time plots). By multivariate analysis, phosphorus =>3,7 mg/dl inversaly and indipendently correlate with cardiovascular mortality in Early and Late groups, with a rduction of risk of 11% and 36% respectively(considering upper limits of HR). This vantage is indipendent from absence of cardiovascular disease and is lost for phosphorus => 3,9 mg/dl. Same analysis for all cause mortality demontrate a reduction risk of 33% in early but no in late group. Interaction for albumin <3,9 gr/dl is significancy for cardiovascular mortality in both groups(P0,05). Same interaction for all cause mortality is significant in early (P0,05) but no in late group(P0,21). Conclusions: Our study demonstred the indirect relationship of cardiovascular mortality with phosphorus, ranging 3,7-3,9 mg/dl (range more close than classic 1mg/ dl), indipendently from nutritional parameter examained (albumin <3,9 gr/dl). This relationship remains similar throughout whole dialysis vintage, beyond time-updating variables. The same is not for all cause mortalit.y Introduction and Aims: REACT is an observational trial to assess intact parathyroid hormone (iPTH) target range achievement with cinacalcet therapy in German dialysis patients with secondary hyperparathyroidism (sHPT) in accordance with both the NKF-DOQI™ and KDIGO® guidelines. Methods: REACT is a multicenter observational trial in 1180 chronic dialysis patients with sHPT from 124 German sites. Cinacalcet therapy had to be initiated prior to inclusion. The primary objective was the relative ( percentage) change in iPTH from baseline (BL) to month 9-12 (quarter 4). Relevant data were collected retrospectively for 6 months and prospectively for 12 months after inclusion. PTH levels were summarized in 3-month periods before and after initiation of cinacalcet. Results: The full analysis set (FAS) consisted of 1180 patients (59% male, mean age 62.5 years (SD14.8 years), mean dialysis vintage 45.3 months, most frequent renal diagnosis: diabetic nephropathy 24% and glomerular nephropathy 20%). Mean iPTH (SD) changed from 616.4 pg/ml (339.28) at BL to 382.1 pg/ml (311.10) at quarter 4 in the FAS (mean reduction 29.4%, SE 2.06).506 (50 %) patients achieved an iPTH reduction of at least 30% from BL to quarter 4. Data for calcium, phosphorus and Ca x P are shown in the Table. Mean (SD) cinacalcet doses (mg/day) were 31.5 (10.73) at baseline and 35.9 (25.44) during quarter 4. No relevant changes were found with respect to concurrent vitamin D compound or oral phosphate binder therapies. Cinacalcet therapy was initiated in 500 (42%) patients before publication of KDIGO® guidelines and in 680 (58%) patients after publication. iPTH-reduction and medical practices with respect to cinacalcet dosing were not different in those two patient groups. At baseline, 426 (42%) patients had an iPTH above KDIGO® target range (> 9x upper normal limit). At quarter 4, 185 (18%) patients still had an iPTH above the KDIGO® target range. Data analysis, stratified by iPTH at baseline, showed an iPTH reduction of 47.2% with baseline iPTH > 800 pg/ml, of 33.9% with iPTH > 500 to ≤ 800 pg/ml, of 26.2% with iPTH > 300 to ≤ 500 pg/ml and of 14.4% with iPTH < 300 pg/ml. Conclusions: In this large observational trial, cinacalcet reduced iPTH regardless of baseline iPTH. A large number of patients achieved an iPTH below the upper KDIGO® limit target range during the trial. No differences in clinical practice were identified when cinacalcet was started before or after publication of KDIGO® guidelines. The results were achieved with remarkably low cinacalcet doses and the number of necessary cinacalcet dose adaptions during the study was moderate. Taken together, the results of this observational trial are consistent with published randomized control trials and further support the use of cinacalcet for the treatment of sHPT in dialysis patients. Introduction and Aims: Eldecalcitol (ELD), a new active vitamin D 3 analog developed in Japan, has been recognized as an effective therapeutic drug for primary osteoporosis. ELD treatment in postmenopausal women undergoing dialysis lead to significant increases in lumbar bone density in our institution; however, in some patients there was a tendency for bone density levels to fall at 6 months after the start of ELD treatment. This was considered to be the result an insufficient effect on anti-bone reabsorption by ELD (Reported at ERA-EDTA 2013). We have, therefore, performed and examined combination treatment with ELD and selective estrogen-receptor modulators (SERMs), an anti-bone reabsorption drug. Methods: Patients who had received ELD treatment for 1 year, were enrolled. Patients were divided into two groups, ELD only (n=15) and ELD/SERMs (n=17), and observed for 6 months. Raloxifen 60 mg/day was administrated as the SERM treatment. Results: Two patients discontinued treatment due to hypercalcemia in the ELD group; however no patients discontinued treatment in ELD/SERMs group. Mean levels of serum bone turnover markers, BAP and TRACP-5b, were significantly increased above the normal range in the ELD group patients; however, levels were significantly decreased to the within their normal ranges in ELD/SERMs group patients. Lumbar bone density was increased in both groups, with no significant difference in %changes between the two groups.
SP586 PHOSPHORUS AND MORTALITY RELATIONSHIP: ANALYSIS CONSIDERING VERY NARROW CUT-OFFS AND CONFOUNDER BEYOND TIME UP-DATING VARIABLES
SP587 CINACALCET THERAPY IN DIALYSIS PATIENTS: RESULTS OF THE GERMAN REACT TRIAL
SP588 COMBINATION TREATMENT WITH ELDECALCITOL AND SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR POSTMENOPAUSAL WOMEN ON DIALYSIS
Conclusions: Combination treatment with SERMs reduces the risk of hypercalcemia associated with ELD treatment, thus increasing the potential for long-term ELD treatment. Table: Mean difference for iPTH, Ca, P and Ca x P from BL to quarter 4 absolute difference (SE) % difference (SE) iPTH -225.9 (11.80)pg/ml -29.4 (2.06)% Ca -0.3 (0.03)mg/dl -2.5 (0.39)% P -0.4 (0.06)mg/dl -2.9 (0.94)% Ca x P -5.6 (0.55)mg2/dl2 -5.4 (1.05)% (25VD), PTH, ferritin, C reactive protein (CRP), Hb, calcium and phosphorus plasma levels were measured in springtime. Vitamin D levels were considered normal when ≥ 30 ng / ml, and S25VDD when < 10ng/ml. Anemia was defined by Hb <10g/dL, and slight anemia included also Pts when epo dose <2000UI/week was needed. High Ferritin was defined by levels over 500 ng/ml, and high C Reactive Protein with levels over 5mg/L. Pts characteristics were compared according to the presence of S25VDD. Risk factors for S25VDD and anemia were analyzed by logistic regression (LR 2013) . Results: Twelve patients are included in this study, the majority (n 9) being on hemodialysis. The majority of lesions were located on the inferior limbs (n 10) with 3 out of 10 complicated with an additional abdominal lesion. Other sites were the abdomen (n 1) and breasts (n 1). Table 1 shows patients characteristics known to be calciphylaxis related : diabete (n 11), calcium-based phosphorus chelators use (n 10), warfarin use (n 9), female gender (n 8), IV iron use (n 8) and obesity (n 7). STS treatment median duration was 105 days. Response was complete in 5 cases and pain relief was obtained in all twelve. Adjunctive treatments included bisphosphonates (n 7), dialysis intensification (n 5) and calcium dialysate concentration lowering (n 6). Half of patients presented nausea episodes which were severe enough to stop STS in 2 cases. One year mortality rate in our patients was 25%, much less than reported in the literature. No factors could be associated with positive treatment response ( Table 2) . Conclusions: Calciphylaxis is a serious complication and is a highly morbid condition associated with CKD. A multimodal approach is suggested for the care of these patients. STS is probably helpful when added to the other adjunctive treatments. Because of the rarity of calciphylaxis, participation to national registries should be promoted.
SP589 ANEMIA ASSOCIATED TO SEVERE VITAMIN D DEFFICIENCY IN HEMODIALYSIS PATIENTS
SP591 MANAGEMENT OF SERUM CHOLESTEROL AND CALCIUM IN PREDIALYSIS PHASE OF CHRONIC KIDNEY DISEASE IS IMPORTANT FOR PREVENTION OF AORTIC CALCIFICATION AFTER HEMODIALYSIS INITIATION
Takayuki Fujii 1 , Satoshi Suzuki 1 , Mizuki Shinozaki 1 and Hiroaki Tanaka 1 1 Seirei Sakura Citizen Hospital, Sakura City, Japan
Introduction and Aims: Vascular calcification is an important risk factor influencing cardiovascular complications and vital prognosis in chronic kidney disease (CKD) patients. We previously reported that the strict management of PTH and reducing the dose of calcium-containing phospphate binder as far as possible are important, regarding vascular calcification in patients new to hemodialysis (at ERA-EDTA2013). However, there are no evidence-based clinical practice guidelines for predialysis CKD patients to prevent from vascular calcification. In this study, we evaluated clinical parameters in predialysis phase of CKD influencing vascular calcification after dialysis initiation. Methods: Among 117 patients who received hemodialysis in our hospital for at least 3 years between September 2004 and June 2010, we selected 63 patients who had been available for follow-up for at least 1 year before dialysis initiation and performed a retrospective cohort study. We compared the extent of calcification in the aortic arch at the time of dialysis initiation and at 3 years later by reviewing postero-anterior chest X-ray. We defined an outcome as the worsening of calcification and examined the factors related to this outcome during predialysis phase by using multiple logistic regression analysis. Results: Forty of the 63 patients reached the outcome. Multivariate analysis, using the mean daily dose of calcium carbonate after dialysis initiation and the clinical parameters in predialysis phase of CKD as covariates, identified the mean serum calcium level and non HDL cholesterol level (every 10mg/dL) as significant independent factors for worsening of aortic calcification, with odds ratios of 2.84 (95% CI 1.14-8.28) and 1.23 (95%CI 1.04-1.53), respectively. On the other hand, no SP589 15.8 ± 18.9 7.6 ± 9.1 0.019 PTH ng/ml(x ± DS) 485 ± 360 424 ± 346 NS SP590
SP590
Introduction and Aims: Calcium-based (CB) phosphate binders are commonly used as first-line treatment of hyperphosphatemia in Chronic Kidney Disease (CKD) in Spain. However, when calcium agents are ineffective or inadequate, a strategy of dose escalation may be inappropriate due to the increased risk of hypercalcemia, related to a higher mortality risk. The aim of this study was to evaluate the cost-effectiveness of the use of Lanthanum Carbonate (LC) as second line treatment in CKD patients irrespective of dialysis status.
Methods: A Markov model was developed considering three health states ( predialysis, dialysis and death) to assess the incremental cost-effectiveness ratio (ICER) of second-line LC treatment in patients, previously treated with CB (calcium carbonate and calcium acetate). Patients entered the model in the predialysis health state. Transitions between states were obtained from randomized clinical trials and from the European Dialysis and Transplant Association annual report. Mortality and CKD progression rates were adjusted using relative risks related to serum phosphate levels. Efficacy data of LC and CB in reducing serum phosphate were obtained from randomized clinical trials. According to Spanish healthcare system perspective, only medical direct costs ( pharmaceutical and dialysis costs) were taken into account. Dialysis costs (2013 prices in Euros) were obtained from diagnosis-related groups. As prolonged dialysis is exclusively related to the extended life of treated patients, dialysis costs in added life years were classified as unrelated future costs and were not considered in the base case analysis. Drug costs were derived from ex-factory prices, adjusted with 7.5% mandatory rebate. Quality of life estimates were based on a published systematic review. All costs and benefits were discounted at a rate of 3% per year. Deterministic and probabilistic sensitivity analyses (PSA) were conducted. Results: Considering a lifelong time horizon, costs per patient associated with LC second line therapy were €1,169, while they were €5,044 with the CB only strategy. Second line LC delayed progression to the dialysis health-state, thereby leading to large cost-savings. On average, patients accrued 4.579 Quality Adjusted Life Years (QALYs) in the LC second line treatment strategy, compared to 4.653 QALYs in the CB only strategy. CB therapy was dominated by the LC strategy. One-way sensitivity analyses revealed that long term dialysis future cost was the most influential parameter in the Introduction and Aims: The aim of this study was to evaluate the variations in some major bone metabolism markers with reference to klotho gene polymorphism (KGP) and bone mineral density (BMD) values in patients on chronic peritoneal dialysis (CPD), hemodialiysis (HD) and renal transplant patients (RTP). Methods: In 27 HD, 51 CPD, 25 RT patients and 40 healthy persons assays for ɑ-klotho gen mutations (DNA extract via real time PCR and high resolution melting (HRM) methods were used), fibroblast growth factor 23 (FGF-23), osteoprotogerin (OPG), osteocalcin (OC), procollagen type-1 N terminal propeptide (PINP), beta-crosslaps (beta CTx), tartrate resistant acid phosphatase (TRAP5b), bone alkaline phosphatase (BAP), 1,25(OH)D3, 25(OH)D3 and intact parathormon (iPTH) were performed.
Results: ɑ-Klotho gen mutations (KL F352V (rs9536314)) were found in only 5 (18,5%) hemodialysis patients and one control subjects, not PD and RTP. FGF 23 levels were also significantly higher in HD group than the other groups (Figure 1) .
Comparison of the groups regarding markers of bone metabolism are shown in Figure 2 . Conclusions: Based on FGF23 levels, other major markers of bone metabolism and bone mineral density, the most effective renal replacement therapy is renal transplantation. 
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